In 2020, Alhopuro et al reported a woman treated for breast cancer at age 36 years who had a BRCA2 c.9294C > G, p.(Tyr3098Ter) pathogenic variant in 57% of tumour reads and at a lower, variable level (between 20 and 36% reads) in four different non-neoplastic tissues [2]. The gene discussed is BRCA2; the disease is breast carcinoma.